Search

Displaying results 3851 - 3860 of 7502 in total
  1. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause.

  2. Drug

    Xylazine

    go.drugbank.com/drugs/DB11477
    InvestigationalVet approved

    [L42675] Xylazine is sometimes used as an adulterant and combined with opioids and recreational drugs; however, it has no antidote, and the use of [naloxone] has no effect on xylazine.[L42675,L42680] … [A32545] Xylazine is not approved for human use and requires a veterinary licence for its purchase and use.

  3. Drug

    Pradefovir mesylate

    go.drugbank.com/drugs/DB05478
    Investigational

    Pradefovir is activated through oxidation that is mediated by cytochrome P-450 (CYP) 3A4, which is predominantly expressed in the liver. … As adefovir is poorly absorbed and associated with a high level of nephrotoxicity, pradefovir mesilate was designed to specifically target the liver and reduce risks to external tissue, especially the

  4. Drug

    Rasagiline

    go.drugbank.com/drugs/DB01367
    ApprovedInvestigational

    Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.

    Synonyms: (1R)-N-propargylindan-1-amine, (R)-N-2-Propynyl-1-indanamineCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    It is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

  6. Drug

    Fedratinib

    go.drugbank.com/drugs/DB12500
    ApprovedInvestigational

    [A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090] … Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.

  7. Drug

    HLX70

    go.drugbank.com/drugs/DB16509
    Investigational

    The condition targeted by HLX70 in this study is COVID-19. … HLX70, a recombinant humanized anti-S protein monoclonal antibody intended for intravenous infusion, was under investigation in clinical trials NCT05429385 and NCT04561076 to evaluate its safety and pharmacokinetics

  8. Drug

    Bevantolol

    go.drugbank.com/drugs/DB01295
    Investigational

    Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. … Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.

  9. Drug

    Dihydroxymethoxychalcone

    go.drugbank.com/drugs/DB14122
    Investigational

    Cardamonin (also known as Dihydroxymethoxychalcone), as shown by the increasing number of publications, has received growing attention from the scientific community due to the expectations toward its benefits … to human health.

  10. Drug

    Isoniazid

    go.drugbank.com/drugs/DB00951
    ApprovedInvestigational

    Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome